Pennsylvania SB1149 amends the Controlled Substance, Drug, Device and Cosmetic Act to schedule synthetic psilocybin in alignment with federal law.
Pennsylvania SB1149 amends the Controlled Substance, Drug, Device and Cosmetic Act to ensure that the pharmaceutical composition of synthetic psilocybin is scheduled in accordance with federal law. This includes aligning with the United States Food and Drug Administration's approval and the United States Drug Enforcement Administration's rescheduling. The secretary must notify the Legislative Reference Bureau within five business days of any federal rescheduling for publication in the Pennsylvania Bulletin.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.